Dalcetrapib

Summary

Dalcetrapib (CHEMBL313006) is a phase-3 clinical-stage small molecule targeting CETP; indicated across 8 conditions including cardiovascular disorder and coronary artery disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (CETP)
• Indications: 8 conditions
• Clinical trials: 15
• Chemistry: 389.6 Da · C23H35NO2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL313006
Name	Dalcetrapib
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918540
Molecular formula	C23H35NO2S
Molecular weight	389.6
InChIKey	YZQLWPMZQVHJED-UHFFFAOYSA-N

SMILES: CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C

IUPAC name: S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate

Also known as: Dalcetrapib, JTT-705, RO-4607381, RO4607381, DALCETRAPIB, DALCETRAPIB (JTT-705), Dalcetrapib£¬JTT-705£©, Dalcetrapib£¨JTT-705£©, Dalcetrapib��JTT-705��

Patent coverage: 469 distinct patent families (1,316 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,313 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CETP	cholesteryl ester transfer protein	Inhibition	5.39	0.2%	P11597

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Cholesteryl ester transfer protein.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CETP	5.39	IC50	4100	nM	CHEMBL_ACT_18143899
CETP	5.22	IC50	6000	nM	CHEMBL_ACT_1129483
CETP	5.22	IC50	6000	nM	CHEMBL_ACT_895197

Target pathways

Aggregated over 1 target gene(s): CETP.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
LDL remodeling	1	CETP
HDL remodeling	1	CETP
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	1	CETP

Dominant GO biological processes

GO term	Targets
triglyceride metabolic process	1
lipid transport	1
cholesterol metabolic process	1
negative regulation of macrophage derived foam cell differentiation	1
regulation of cholesterol efflux	1
cholesterol transport	1
positive regulation of cholesterol transport	1
triglyceride transport	1
very-low-density lipoprotein particle remodeling	1
low-density lipoprotein particle remodeling	1
high-density lipoprotein particle remodeling	1
cholesterol homeostasis	1
reverse cholesterol transport	1
phosphatidylcholine metabolic process	1
lipid homeostasis	1

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
coronary artery disorder	3	MONDO:0005010	EFO:0001645
acute coronary syndrome	3	MONDO:0005542	EFO:0005672
peripheral arterial disease	3	MONDO:0005386	EFO:0004265
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
hyperlipidemia	2	MONDO:0021187	MONDO:0021187

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	6
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05918861	PHASE3	RECRUITING	Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT00658515	PHASE3	COMPLETED	A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
NCT01059682	PHASE3	TERMINATED	A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
NCT01323153	PHASE3	COMPLETED	A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
NCT01516541	PHASE3	COMPLETED	A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
NCT02525939	PHASE3	COMPLETED	Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
NCT00353522	PHASE2	COMPLETED	A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
NCT00400439	PHASE2	COMPLETED	A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381
NCT00655473	PHASE2	COMPLETED	A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
NCT00655538	PHASE2	COMPLETED	A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
NCT00686010	PHASE2	COMPLETED	Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
NCT00697203	PHASE2	COMPLETED	A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)
NCT04676867	PHASE2	COMPLETED	Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
NCT01363999	PHASE1	COMPLETED	A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers
NCT01476267	PHASE1	COMPLETED	A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

4 molecules share ≥1 primary target. Top 4 by shared-target count:

Molecule	Source	Status	Shared targets
ANACETRAPIB	ChEMBL	Phase 3	CETP
EVACETRAPIB	ChEMBL	Phase 3	CETP
TORCETRAPIB	ChEMBL	Phase 3	CETP
URSOLIC ACID	ChEMBL	Phase 2	CETP